Actively Recruiting
Evaluation of Multiple Therapies in Biomarker-Selected Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Including Neoadjuvant and Adjuvant Treatment
Led by Genentech, Inc. · Updated on 2026-10-13
99
Participants Needed
38
Research Sites
182 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of multiple therapies in participants with early-stage non-small cell lung cancer NSCLC at stages IB through III, including selected IIIB tumors that are resectable and untreated, and meet specific biomarker criteria. This Phase II trial focuses on different treatment approaches based on genetic and molecular features of the tumors. The study aims to assess how well these therapies work before and after surgery to improve outcomes for patients with NSCLC. Participants receive up to 8 weeks of neoadjuvant therapy with one of several study drugs, including alectinib, entrectinib, vemurafenib plus cobimetinib, pralsetinib, atezolizumab combined with stereotactic body radiation therapy SBRT, or divarasib, depending on their biomarker status. After this initial treatment period, participants undergo surgical removal of the tumor following standard care. Those whose tumors show a pathological response or no disease progression then receive adjuvant therapy, which typically includes 4 cycles of chemotherapy followed by up to 2 years of continued therapy with the initial study drug or other specified treatments. Throughout the trial, participants are monitored with imaging scans such as CT, PET, and brain MRI, along with laboratory tests to assess tumor response and safety. Researchers measure outcomes including major pathologic response, complete pathological response, adverse events, and survival rates over up to nine years. The study also evaluates detailed biomarkers like circulating tumor DNA and drug levels in plasma. Participant involvement includes neoadjuvant treatment, surgery, adjuvant therapy, and long-term follow-up visits to track disease-free and overall survival as well as treatment effects.
CONDITIONS
Brief Title
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Research Team
R
Reference Study ID Number: ML41591 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here